News | News By Subject | News by Disease News By Date | Search News

Lymphoma, Non-Hodgkin's News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Kite Pharma (KITE)'s CAR-T Blood Cancer Candidate Succeeds in Major Study     3/2/2017
On a Roll: Kite Pharma (KITE) Bags $250 Million CAR-T Deal From Daiichi Sankyo, Inc. (DSNKY), Forms Joint Venture With Fosun Pharma     1/11/2017
Kite Pharma (KITE) Claims Success for Phase II CAR-T Study, Stock Soars     9/28/2016
Good News for Gilead (GILD) as Zydelig Passes Safety Review Test Despite Trial Deaths     7/12/2016
This Year’s Top 10 Disappointing Clinical Trials—So Far!     7/6/2016
Epizyme (EPZM), Genentech (RHHBY) Join Forces for Tazemetostat and Tecentriq Trial in Non-Hodgkin Lymphoma     6/23/2016
Epizyme (EPZM) to Continue Blood Cancer Trials as Tumors Were Wiped Out in Some Patients     6/21/2016
Infinity Pharma (INFI) to Eliminate 46 Researchers After Lymphoma Drug Disappoints in Study     6/14/2016
SoCal's Kite Pharma (KITE) Grabs a Clinical Trial Cancer Deal with Genentech (RHHBY)     3/17/2016
Eisai Company (ESALY.PK) Buys Cancer Drug Rights From HUYA Bioscience in $280 Million+ Deal     2/1/2016
Genentech (RHHBY) Touts Hematology Data for Gazyva and Venetoclax in CLL     12/17/2015
Kite Pharma (KITE) Surges as FDA Grants Breakthrough Tag for Lymphoma Drug     12/7/2015
Top 10 Best-Selling Biotech Drugs     10/2/2015
Amgen (AMGN) Deal Brings Xencor $45M Up Front, Setup for $1.7B in Milestones     9/16/2015
Kite Pharma (KITE) CEO Refutes Rumors of Death Associated with Experimental Cancer Drug     8/18/2015

News from Around the Web
Possible Drug Targets for Common Non-Hodgkin's Lymphoma Discovered, University of Maryland Study     7/20/2011
New Potential Drug Combination for Most Common Form of Non-Hodgkin's Lymphoma, Weill Cornell Medical College Study     11/2/2010
How Dietary Supplement May Block Cancer Cells, Ohio State University Study     7/1/2010
Stanford University School of Medicine Study Finds Tobacco Plant Could Actually Aid Patients with Non-Hodgkin's Lymphoma     7/22/2008
National Cancer Institute Studying Mutations in Non-Hodgkin Lymphoma Yields Clues for Potential New Therapies     3/10/2008
Cancer Drug Slows Multiple Sclerosis Progression     2/14/2008
"C" to Believe: Thomas Jefferson University Scientists Studying the Effects of High Dose Vitamin C on Non-Hodgkin Lymphoma Patients     1/3/2008
Some Sun May Guard Against Non-Hodgkin's Lymphoma     1/2/2008
Scientists Discover New Genetic Subtypes Of Common Blood Cancer     4/10/2006
New Drug From Human Genome Sciences: Investment Potential?     7/6/2005
Alcohol Seems To Lower Risk Of Non-Hodgkin Lymphoma     6/7/2005
Lymphoma Treatment Shows Promise     2/3/2005
Allergy Link To Blood Cancer Risk     11/4/2004
Monkey Virus Exposure Did Not Raise Lymphoma Risk     9/15/2004
Unusual DNA May Be Key To Cancer     3/4/2004

Press Releases
Immune Design Corporation (IMDZ) Receives Orphan Drug Designation For G100 Intratumoral Product Candidate     2/22/2017
AbbVie (ABBV) Release: U.S. FDA Approves Imbruvica (Ibrutinib) As First Treatment Specifically Indicated For Relapsed/Refractory Marginal Zone Lymphoma (Mzl) - A Rare Type Of Non-Hodgkin's Lymphoma     1/19/2017
Eisai Company (ESALY.PK) Release: Anticancer Agent Treakisym Approved In Japan For Additional Indication As First-Line Treatment For Low-Grade B-Cell Non-Hodgkin's Lymphoma And Mantle Cell Lymphoma     12/22/2016
Roche Canada Release: New Formulation Of RITUXAN Now Available To Canadians Living With Non-Hodgkin's Lymphoma     12/13/2016
Kite Pharma (KITE) Presents Results Of Multi-Center Pivotal ZUMA-1 Trial Of Axicabtagene Ciloleucel (KTE-C19) In Aggressive Non-Hodgkin Lymphoma As Late-Breaking Abstract At Annual Meeting Of American Society of Hematology     12/6/2016
Juno (JUNO) Lymphoma Drug Impresses in Early Stage Study, But Fear of Cerebral Edema Looms     12/6/2016
Janssen R&D Release: New Ibrutinib (IMBRUVICA) Phase 2 Data Demonstrate Promise In Relapsed/Refractory Marginal Zone Lymphoma (MZL), A Rare, Incurable Type Of Non-Hodgkin's Lymphoma     12/6/2016
Cornerstone Pharmaceuticals, Inc. Presents Phase I Data On CPI-613 In Acute Myeloid Leukemia (AML) And T-Cell Non-Hodgkin's Lymphoma (T-Cell NHL) At American Society of Hematology 2016     12/6/2016
Juno (JUNO) Presents Data From TRANSCEND Study Showing 60% Complete Response In Patients With Relapsed Or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma     12/6/2016
Nordic Nanovector: Betalutin In Combination With Rituximab Demonstrates Synergistic Anti-Tumour Effect In Preclinical Non-Hodgkin Lymphoma Model     12/6/2016
Sutro Biopharma ADC Targeting CD74 Exhibits Potent Anti-Tumor Activity In Multiple Malignant Cell Lines And Animal Models Of Non-Hodgkin Lymphoma And Multiple Myeloma     12/6/2016
AbbVie (ABBV) Release: Favorable Response Rates Suggest Promise Of Ibrutinib (IMBRUVICA) Combination Therapy In Two Common Types Of Non-Hodgkin's Lymphoma     12/5/2016
Immune Design Corporation (IMDZ) Provides Update From Two Discovery Platforms: DC-Tropic Zvex Delivering Multiple Tumor Antigens (Conserved And Neo-Antigens) And G100 For Intratumoral Immunotherapy     12/5/2016
Bristol-Myers Squibb (BMY) Release: New Results Presented For Opdivo (Nivolumab) Demonstrate Encouraging Response Rate In An Expanded Population Of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients     10/25/2016
Kite Pharma (KITE) Presents 12-Month Follow-Up Data From ZUMA-1 Phase I At The European Society For Medical Oncology (ESMO) Annual Congress     10/7/2016